Abstract
The World Health Organization (WHO) classifies epithelioid trophoblastic tumour (ETT) as a category of gestational trophoblastic neoplasia (GTN). Initially scripted by Shih and Kurman in 1998, the exceptional epithelioid trophoblastic tumour emerges as a derivative of neoplastic, chorionic- type, intermediate trophoblastic tissue and is associated with a variable clinical representation [1]. Epithelioid trophoblastic tumour may frequently coexist with placental-site trophoblastic tumour and the entities necessitate appropriate segregation. Nevertheless, a comprehensive, universally accepted protocol of tumour discernment, appropriate therapeutic regimen and duration of therapy for epithelioid trophoblastic tumour remains obscure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Clinical and Medical Images, Case Reports
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
